Abstract
The selective sodium hydrogen exchanger 3 (NHE3) inhibitor tenapanor is being developed by Ardelyx Inc. for the treatment of constipation-predominant ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
